[Current and future therapeutic options for COVID-19]
Nederlands Tijdschrift voor Geneeskunde
; 166:21, 2022.
Article
in Dutch
| MEDLINE | ID: covidwho-2011184
ABSTRACT
The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.
Adrenal Cortex Hormones; Anti-Inflammatory Agents/tu [Therapeutic Use]; Antiviral Agents/tu [Therapeutic Use]; COVID-19/dt [Drug Therapy]; *covid-19; Guanosine Monophosphate/aa [Analogs & Derivatives]; Humans; Phosphoramides; Recombinant Fusion Proteins; SARS-CoV-2; 0 (at-511); 0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents); 0 (Antiviral Agents); 0 (Phosphoramides); 0 (Recombinant Fusion Proteins); 85-32-5 (Guanosine Monophosphate); PV6AA88RDU (ensovibep)
Search on Google
Collection:
Databases of international organizations
Database:
MEDLINE
Language:
Dutch
Journal:
Nederlands Tijdschrift voor Geneeskunde
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS